Amgen presents data from study of the pivotal phase 3 prolia fracture trial
Amgen Inc. announced that it has presented data from several sub-analyses at ASBMR From the ongoing open-label extension study of the pivotal phase 3 prolia fracture trial.
Amgen Inc., a unit of Takeda Pharmaceutical Co. has been forced to suspend a late-stage trial of a very promising cancer drug.